Adaptin Bio Opens Enrollment in Phase 1 Trial for Brain Tumor Therapy APTN-101
APTN is trading near its 52-week low of $5.6 (12% above the low).
Summary
Adaptin Bio has opened enrollment for a first-in-human Phase 1 trial of APTN-101, its BRiTE bispecific T-cell engager targeting EGFRvIII-positive glioblastoma. The open-label, dose-escalation study at Duke University will enroll up to 15 patients, with safety and maximum tolerated dose as primary endpoints. Preclinical data showed complete tumor eradication in 70-80% of mice and a 7-fold increase in brain distribution, supporting the novel blood-brain barrier delivery mechanism. This milestone follows the Q2 10-Q filed August 13, which disclosed going concern doubt and ongoing dilution from warrant exercises. For a micro-cap biotech trading near its 52-week high, advancing a differentiated oncology asset into the clinic is a meaningful de-risking event, though the company's financial fragility remains a key risk. Initial safety data will be the next major readout.
At the time of this announcement, APTN was trading at $6.27 on OTC in the Life Sciences sector. The 52-week trading range was $5.60 to $6.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.